Difference between revisions of "Sintilimab (Tyvyt)"
Jump to navigation
Jump to search
m |
m |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
From [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sintilimab NCI Drug Dictionary]: A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells. | From [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sintilimab NCI Drug Dictionary]: A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells. | ||
| − | = | + | ==Diseases for which it is used== |
| − | ===[[Non-small cell lung cancer]] | + | *[[Esophageal squamous cell carcinoma]] |
| − | + | *[[Hepatocellular carcinoma]] | |
| − | + | *[[Classical Hodgkin lymphoma]] | |
| − | + | *[[Non-small cell lung cancer]] | |
| − | + | **[[Non-small cell lung cancer, nonsquamous]] | |
| + | **[[Non-small cell lung cancer, squamous]] | ||
| + | ==History of changes in NMPA indication== | ||
| + | *2018-12-24: Initial approval | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' IBI 308 | + | *'''Code name:''' IBI-308 |
| − | *'''Brand | + | *'''Brand names:''' Daboshu, Tyvyt |
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 19: | Line 22: | ||
[[Category:Esophageal squamous cell carcinoma medications]] | [[Category:Esophageal squamous cell carcinoma medications]] | ||
| + | [[Category:Hepatocellular carcinoma medications]] | ||
| + | [[Category:Classical Hodgkin lymphoma medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
| + | [[Category:Non-small cell lung cancer, nonsquamous medications]] | ||
| + | [[Category:Non-small cell lung cancer, squamous medications]] | ||
| − | [[Category:NMPA approved drugs]] | + | [[Category:NMPA approved in 2018]] |
| + | [[Category:PMDA approved drugs]] | ||
Latest revision as of 01:17, 7 November 2023
Mechanism of action
From NCI Drug Dictionary: A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.
Diseases for which it is used
- Esophageal squamous cell carcinoma
- Hepatocellular carcinoma
- Classical Hodgkin lymphoma
- Non-small cell lung cancer
History of changes in NMPA indication
- 2018-12-24: Initial approval
Also known as
- Code name: IBI-308
- Brand names: Daboshu, Tyvyt
Categories:
- Drugs
- Intravenous medications
- Anti-PD-1 antibodies
- Esophageal squamous cell carcinoma medications
- Hepatocellular carcinoma medications
- Classical Hodgkin lymphoma medications
- Non-small cell lung cancer medications
- Non-small cell lung cancer, nonsquamous medications
- Non-small cell lung cancer, squamous medications
- NMPA approved in 2018
- PMDA approved drugs